ArticleFrontiers in oncology2025
Relationship between immunohistochemical markers and clinical pathological variables in clear cell renal cell carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Chemokines CCL3 and CCL7 as Complementary Diagnostic Biomarkers Across Tumor Grades in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the factors associated with the immunohistochemical results in clear cell renal cell carcinoma (ccRCC). Methods: This retrospective, single-center observational study included patients with pathologically confirmed ccRCC who underwent nephrectomy at Xingtai People's Hospital between January 2023 and October 2024. Logistic and linear regression was used to evaluate predictors of ccRCC features, with adjustments for demographic and clinical factors. Result: Among the 50 patients (median age, 66 years; 64% male), high Vimentin expression was significantly associated with vascular invasion (adjusted OR, 2.90; 95% CI, 1.05-7.62; P = 0.031), lymph node metastasis (OR, 2.62; 95% CI, 1.03-8.12; P = 0.042), distant metastasis (OR, 3.10; 95% CI, 1.01-12.54; P = 0.048), and larger tumor size (P = 0.004). Ki-67 expression varied significantly by alcohol consumption (P = 0.024), perineural invasion (P = 0.038), and was positively correlated with serum creatinine (P = 0.017). CD10 expression was inversely correlated with bilirubin levels (P = 0.021) but not associated with invasive or metastatic features. Conclusion: Vimentin expression was strongly associated with markers of tumor invasiveness and may serve as a practical prognostic biomarker in ccRCC. Ki-67 may reflect proliferative activity and systemic burden. CD10 remains diagnostically useful but lacks prognostic value. Incorporating these IHC markers into routine pathology assessment may enhance risk stratification and inform individualized management of ccRCC with more exploration and validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.